Boussard & Gavaudan Investment Management’s Jaws Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary JWS.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-166,666
Closed -$550K 153
2021
Q1
$550K Hold
166,666
0.05% 65
2020
Q4
$483K Hold
166,666
0.07% 52
2020
Q3
$367K Buy
+166,666
New +$358K 0.05% 46

Other funds holding JWS.WS

Boussard & Gavaudan Investment Management's JWS.WS Position: Q2 2021 in Review

Boussard & Gavaudan Investment Management sold out of Jaws Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary (JWS.WS) in Q2 2021, closing a stake of 166,666 shares — an estimated $550K sold.

Boussard & Gavaudan Investment Management first reported a position in JWS.WS in Q3 2020 and held it in 3 quarters. The position peaked at $550K in Q1 2021. 1 fund tracked by Wall St. Rank holds JWS.WS as of Q2 2021.

  • Boussard & Gavaudan Investment Management reported no remaining Jaws Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary position as of Q2 2021 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 166,666 Jaws Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary shares in Q2 2021, an estimated $550K.
  • Boussard & Gavaudan Investment Management first reported a position in Jaws Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary in Q3 2020 and held it in 3 quarters.
  • Boussard & Gavaudan Investment Management's Jaws Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary position peaked at $550K in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Jaws Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary as of Q2 2021.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q2 2021, filed 6 Aug 2021.